EG 427 wins key funding from Bpifrance

EG 427 received 360 000 € from Bpifrance to advance the pharmaceutical development of its first gene therapy candidate. The funds are part of Bpifrance’s supports to innovation through its Aide au Développement de l’Innovation (ADI) program.

×

By clicking Consent, you accept the saving of all cookie data on your device. If you click Denied, only the data necessary for the website to function is saved. More information about cookies in the privacy policy.

settings Reject I agree
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.